8-K


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  September 22, 2015

CVS HEALTH CORPORATION
(Exact Name of Registrant
as Specified in its Charter)

 
 
Delaware
 
 
 
 
(State or Other Jurisdiction of Incorporation)
 
 
 
 
 
 
 
001-01011
 
 
 
05-0494040
(Commission File Number)
 
 
 
(IRS Employer Identification No.)

One CVS Drive
 
 
Woonsocket, Rhode Island
 
02895
(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s telephone number, including area code:  (401) 765-1500


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


1



Item 8.01      Other Events.

On September 22, 2015, CVS Health Corporation (the “Company”) issued a press release announcing that it has commenced (i) private exchange offers to eligible holders to exchange any and all outstanding 4.75% Senior Notes due 2022 and 5.00% Senior Notes due 2024 issued by Omnicare, Inc. (the “Omnicare Notes”) for new notes issued by the Company and cash payments and (ii) a solicitation of consents to amend the indentures under which the Omnicare Notes were issued.

Item 9.01                   Financial Statements and Exhibits.

(d)         Exhibits

99.1     
Press Release, dated September 22, 2015, of CVS Health Corporation.


2




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
CVS HEALTH CORPORATION
 
 
 
By:
/s/ David M. Denton
 
 
David M. Denton
 
 
Executive Vice President and
 
 
Chief Financial Officer
 
 
 
 
 
Dated:
September 22, 2015




3